Drug intelligence / Profile preview

crotalus atrox antivenin

Development stage
Unknown
Lead developer
Bio-Technology General
Modality
Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Crotalus atrox antivenin is a biologic drug consisting of purified immunoglobulin fragments (typically Fab or F(ab')2) derived from the plasma of sheep (ovine) that have been immunized with venom from the Western Diamondback rattlesnake (Crotalus atrox). The preparation contains antibodies that specifically bind and neutralize toxins present in the venom, thereby preventing or reversing systemic toxicity following envenomation. The product is indicated for intravenous administration in adult and pediatric patients who have sustained bites from Crotalinae snakes, including rattlesnakes such as Crotalus atrox. It is produced by fractionating and purifying monospecific snake antivenins using chromatographic techniques[2][7]. CroFab, a commonly used brand, contains a mixture of Fab fragments targeting several North American pit viper venoms, including Crotalus atrox[6][7].

Brand names
CroFab
Other names
Crotalus atrox immune fab antivenin (ovine)
02

Targets

svPLA2 (Snake venom phospholipase A2)

Beyond the preview

Go deeper on crotalus atrox antivenin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on crotalus atrox antivenin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call